A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network
The relative benefit of selecting higher efficacy treatments may vary depending on patients' baseline brain atrophy risk. Poor outcomes are predicted in individuals with high baseline risk who are treated with low-efficacy DMTs.
Authors
- Cynthia Grossman (ORCID: https://orcid.org/0000-0002-5849-6235)
- Kathryn C. Fitzgerald (ORCID: https://orcid.org/0000-0003-3137-0322)
- Le H. Hua (ORCID: https://orcid.org/0000-0002-0535-3978)
- Elias S. Sotirchos (ORCID: https://orcid.org/0000-0002-8812-1637)
- Robert T. Naismith (ORCID: https://orcid.org/0000-0003-0520-4283)
- Nolan Campbell (ORCID: https://orcid.org/0000-0002-9266-2030)
- Carrie M. Hersh (ORCID: https://orcid.org/0000-0002-5716-5645)
- Fabio Pellegrini (ORCID: https://orcid.org/0000-0001-5705-8615)
- Zhaonan Sun (ORCID: https://orcid.org/0000-0001-5333-4387)
- Devon Conway (ORCID: https://orcid.org/0000-0001-5359-6686)
- Tjalf Ziemssen
Institutions
- Biogen (United States) (US)
- Cleveland Clinic (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Johns Hopkins Medicine (US)
- Lou Ruvo Brain Institute (US)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1016/j.msard.2024.105847
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Biogen